Anthropic Pays $400M for 8-Month-Old AI Drug Startup

Competition: Eli Lilly signed a $2.75 billion AI drug research deal with Insilico Medicine in March 2026, while Google DeepMind's Isomorphic Labs prepares human trials.

Anthropic has acquired Coefficient Bio, an eight-month-old AI pharma startup with fewer than ten employees, for roughly $400 million in shares, according to reporting by The Information and Newcomer. Both Anthropic and Coefficient Bio declined to comment on the acquisition, making this Anthropic's boldest move yet into pharmaceutical AI.

Billions are now flowing into AI-powered drug research from both tech giants and traditional pharma. Google DeepMind has spun off Isomorphic Labs as a dedicated AI medicine company, while Eli Lilly recently committed billions to Insilico Medicine.

Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, both formerly of Genentech's Prescient Design unit, where they worked on computational approaches to drug research. At Coefficient Bio, the pair built a platform applying AI for pharmaceutical research, including research planning and identifying new drug opportunities. Despite the company's small size and brief history, Anthropic valued Stanton and Frey's specialized expertise at roughly $40 million per employee, based on the reported deal terms.

Stanton and Frey's team is joining Anthropic's Healthcare and Life Sciences division under Eric Kauderer-Abrams, who has led Anthropic's push into the pharmaceutical sector since October 2025.

Venture capital firm Dimension, which held about half of Coefficient Bio, is reporting a 38,513 percent return on the Coefficient Bio deal, according to Newcomer. For a startup not yet a year old, that figure demonstrates how fiercely AI companies are competing for pharmaceutical AI expertise.

As a result, the roughly $40 million per-employee valuation reveals that Anthropic views pharmaceutical AI talent as scarce enough to command premiums typically reserved for biotech companies with drug candidates already in clinical trials. Anthropic is not buying a product pipeline; it is buying the people who can build one.

Acquiring Coefficient Bio builds on months of healthcare infrastructure investment. Anthropic launched Claude for Life Sciences in October 2025, followed by Claude for Healthcare at JPM26 in January 2026 with HIPAA-ready products.

Building on these partnerships, Anthropic already works with Sanofi, Novo Nordisk, and AbbVie through its pharmaceutical sector healthcare partnerships. According to a Sanofi representative, Claude is used by the majority of employees daily, with efficiency gains reported across the value chain. Claude for Life Sciences connects to research platforms including Benchling, 10x Genomics, PubMed, ClinicalTrials.gov, and Medidata.

From platform tools to pharma partnerships to an outright acquisition in six months, Anthropic's trajectory indicates the company is positioning itself not merely as an AI vendor to the pharmaceutical industry but as a vertically integrated competitor within it.

Meanwhile, with Coefficient Bio's founders now in-house, Anthropic shifts from selling AI tools to pharma companies toward building its own drug research capability. In December 2025, Anthropic acquired Bun, a JavaScript runtime, and in April 2026 it shipped technology from its Vercept AI acquisition, establishing a pattern of acqui-hires across multiple domains.

Competition for AI pharma talent is intensifying across the industry. According to market reports, Eli Lilly and Insilico Medicine signed a $2.75 billion AI drug research deal for licensing in March 2026. However, Eli Lilly's approach targets licensing AI-generated drug candidates rather than acquiring a team outright, a fundamentally different strategy from Anthropic's acqui-hire model.

Google DeepMind's Isomorphic Labs, which signed major research collaborations with Novartis and Eli Lilly in 2024, unveiled its Drug Design Engine in February 2026 and is preparing to test AI-designed drugs in humans. Together, these moves define three distinct models now competing for dominance in pharmaceutical AI: Eli Lilly's licensing approach, Isomorphic's dedicated spinoff, and Anthropic's acqui-hire strategy.

For patients waiting on new treatments, the stakes extend well beyond corporate strategy. Isomorphic expects to begin human trials of AI-designed compounds within the next twelve months, and Eli Lilly's Insilico partnership targets active drug candidates. Whether Stanton and Frey's small team can translate their Genentech expertise into Claude-powered research tools fast enough to keep pace will test whether acqui-hires can match the speed of billion-dollar licensing deals and purpose-built spinoffs in delivering new therapies to clinical trials.